EUVIMEDEUVIMED entdecken
Leserbrief

Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses

André Pontes-Silva

Clinical Rheumatology · 2026-02 · 45 (2) · 1609-1611

DOI: 10.1007/s10067-025-07903-0 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Rheumatology, online erschienen am 03.01.2026. Verfasst von André Pontes-Silva. Beteiligte Einrichtung: Postgraduate Program in Physical Therapy, Department of Physical Therapy, Federal University of Sao Carlos (UFSCar), São Carlos, SP, Brazil. contato.…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Postgraduate Program in Physical Therapy, Department of Physical Therapy, Federal University of Sao Carlos (UFSCar), São Carlos, SP, Brazil. contato.andrepsilva@gmail.com.

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Pontes-Silva, A. (2026). Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses. Clinical Rheumatology, 45(2), 1609-1611. https://doi.org/10.1007/s10067-025-07903-0

Vancouver

Pontes-Silva A. Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses. Clinical Rheumatology. 2026;45(2):1609-1611. doi:10.1007/s10067-025-07903-0

BibTeX
@article{PontesSilva2026,
  author = {Pontes-Silva, André},
  title = {Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {2},
  pages = {1609--1611},
  doi = {10.1007/s10067-025-07903-0}
}
Kostenlos starten →